Vertex Announces Progress In Povetacicept Development Program And Presentation Of New Data At American Society Of Nephrology Kidney Week
RefinitivLesedauer weniger als 1 min
Vertex Pharmaceuticals Inc VRTX:
VERTEX ANNOUNCES PROGRESS IN POVETACICEPT DEVELOPMENT PROGRAM AND PRESENTATION OF NEW DATA AT AMERICAN SOCIETY OF NEPHROLOGY KIDNEY WEEK
VERTEX PHARMACEUTICALS INC - FDA GRANTS ROLLING REVIEW FOR POVETACICEPT IN IGA NEPHROPATHY
VERTEX PHARMACEUTICALS INC: EXPECTS TO SUBMIT FIRST MODULE TO FDA FOR POTENTIAL ACCELERATED APPROVAL BEFORE END OF 2025
VERTEX PHARMACEUTICALS INC: REMAINS ON TRACK TO COMPLETE FULL BLA SUBMISSION FOR ACCELERATED APPROVAL IN U.S. IN FIRST HALF OF 2026
Loggen Sie sich ein oder erstellen Sie ein fortwährend kostenloses Konto, um diese News lesen zu können